Online inquiry

IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1310MR)

This product GTTS-WQ1310MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MET gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000245.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4233
UniProt ID P08581
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1310MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12756MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ5162MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ8955MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ13510MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PRX002
GTTS-WQ14197MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ8956MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ11351MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ3950MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW